Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer (scientific article published on 4 February 2016)

Loss of PTEN Expression by Blocking Nuclear Translocation of EGR1 in Gefitinib-Resistant Lung Cancer Cells Harboring Epidermal Growth Factor Receptor–Activating Mutations

Q39642171

Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer

Q42815191

Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers

Q43598203

EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.

Q53381227

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.

Q54578092

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

Q24649549

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

Q24649935

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

Q27851406

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Q27851712

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

Q27851896

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

Q27852553

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

Q27853013

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer

Q27853158

Rociletinib in EGFR-mutated non-small-cell lung cancer

Q27853159

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.

Q27853162

Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation

Q28271532

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Q29547545

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Q29619975

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Q29620648

The quest to overcome resistance to EGFR-targeted therapies in cancer

Q33725976

Large-scale East-Asian eQTL mapping reveals novel candidate genes for LD mapping and the genomic landscape of transcriptional effects of sequence variants

Q33793911

Patient-derived models of acquired resistance can identify effective drug combinations for cancer.

Q34447778

Chemoradiation provides a physiological selective pressure that increases the expansion of aberrant TP53 tumor variants in residual rectal cancerous regions

Q34654543

Collateral chemoresistance to anti-microtubule agents in a lung cancer cell line with acquired resistance to erlotinib

Q35602423

Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers

Q35964699

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies

Q36104980

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

Q36128435

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.

Q36140332

HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation

Q36322762

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

Q36687288

Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins

Q36726112

Acquired resistance to TKIs in solid tumours: learning from lung cancer

Q38224967

Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor

Q38880070

Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models

Q38887681

P433

issue

P304

page(s)

461-468

P577

publication date

2016-02-04

P1433

published in

Cancer Science

Q326125

P1476

title

Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer

P478

volume

107

Reverse relations

cites work (P2860)

Q92324835	BH3 mimetic ABT-263 enhances the anticancer effects of apigenin in tumor cells with activating EGFR mutation
Q58749346	Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions
Q37669061	Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy-Naive Isogenic Lung Cancer Lesions with EGFR Mutation
Q47098234	Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines
Q57142923	Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment-Naïve Lesions
Q88802600	Loss of EGFR confers acquired resistance to AZD9291 in an EGFR-mutant non-small cell lung cancer cell line with an epithelial-mesenchymal transition phenotype
Q37427045	MEK inhibitors against MET-amplified non-small cell lung cancer
Q47146662	Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer
Q38682189	Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms
Q58792324	Personalized therapy for lung cancer: Striking a moving target
Q53718494	Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma.
Q51004850	Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling.
Q38746756	Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells
Q34550460	Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance.
Q28069708	Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors